Epiyangambin

Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells) [1][2].

Product Specifications

CAS Number

[24192-64-1]

UNSPSC

12352005

Hazard Statement

H315-H319-H335

Target

Platelet-activating Factor Receptor (PAFR)

Type

Natural Products

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/epiyangambin.html

Solubility

10 mM in DMSO

Smiles

COC1=C(OC)C(OC)=CC([C@H]2OC[C@]3([H])[C@H](C4=CC(OC)=C(OC)C(OC)=C4)OC[C@@]32[H])=C1

Molecular Formula

C24H30O8

Molecular Weight

446.49

Precautions

P261-P264-P271-P280-P302+P352-P304+P340-P362+P364-P405-P501

References & Citations

[1]Hausott B, et al. Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells. J Cancer Res Clin Oncol. 2003 Oct;129 (10) :569-76.|[2]Castro-Faria-Neto HC, et al. Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity. J Lipid Mediat. 1993 May;7 (1) :1-9.